Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the transaction, the insider now owns 1,174,662 shares in the company, valued at $18,818,085.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Day One Biopharmaceuticals Trading Up 2.8 %

Shares of DAWN stock opened at $15.38 on Tuesday. The firm has a fifty day simple moving average of $15.22 and a 200-day simple moving average of $13.75. The company has a market capitalization of $1.34 billion, a PE ratio of -6.46 and a beta of -1.48. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Day One Biopharmaceuticals by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock worth $56,807,000 after buying an additional 346,090 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 38.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock worth $5,486,000 after purchasing an additional 125,050 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after purchasing an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in Day One Biopharmaceuticals by 41.8% in the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock valued at $14,020,000 after buying an additional 336,910 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in Day One Biopharmaceuticals by 5.5% during the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after buying an additional 9,219 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on DAWN shares. JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.83.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.